Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Whole Genomic Landscape of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Treated With First-Line Osimertinib (WARRIOR)

NCT03969823 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT03969823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03969823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Whole Genomic Landscape of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Treated With First-Line Osimertinib (WARRIOR)
Lead sponsor
Seoul National University Hospital
Phase
Not applicable
Overall status
Active, not recruiting
Start date
May 23, 2019
Completion date
December 31, 2026
Enrollment
148 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic nsclc